OliX emphasizes that collaboration on OLX702A is proceeding normally, with clinical reporting schedules maintained.
The macular degeneration treatment candidate OLX301A has successfully passed ethics review for Phase 2a clinical trials in New Zealand.
OliX has officially denied rumors suggesting a rift in its partnership with Eli Lilly regarding the drug candidate OLX702A. The company confirmed that the Clinical Study Report (CSR) containing the results of the Phase 1 clinical trial in Australia is still expected to be received within this year, as originally planned.
Collaboration with Eli Lilly Proceeding Normally; "Refer to Official Disclosures"
OliX addressed recent misinformation circulating about OLX702A, clarifying that its collaboration with Eli Lilly is proceeding as intended and that claims of a strained relationship are unfounded. The company urged shareholders to rely on official disclosures and announcements rather than unverified information, noting that all major management and R&D developments are disclosed in accordance with regulatory requirements.
OLX702A is a therapeutic candidate for metabolic dysfunction-associated steatohepatitis (MASH) and obesity. OliX entered into a joint development and licensing agreement with Eli Lilly in February of last year, under which OliX completes Phase 1 trials, while Eli Lilly oversees subsequent R&D and commercialization.
According to materials released during the company's R&D Day in July, the multiple-ascending dose portion of the Australian Phase 1 trial concluded its final patient visit in May. The company is currently awaiting the final CSR.
Macular Degeneration Treatment Passes New Zealand Ethics Review
The macular degeneration treatment candidate OLX301A has passed the ethics review for its Phase 2a clinical trial in New Zealand. OliX announced on the 10th that it received a notice of approval from the Health and Disability Ethics Committees (HDEC) of New Zealand, following a successful resubmission of supplementary data after an initial rejection last month.
To commence local clinical trials, the company must still obtain separate approval for its clinical trial application from Medsafe, the local pharmaceutical regulatory authority. The application was submitted on September 30, and the company is currently awaiting the results of that review.
This clinical trial aims to evaluate the efficacy and safety of OLX301A in patients with age-related macular degeneration accompanied by geographic atrophy (GA). GA is an advanced form of dry macular degeneration that causes vision loss due to retinal cell damage.
OliX also received approval for its Phase 2a clinical trial plan for OLX301A in Australia last month and has submitted its clinical trial application to the U.S. Food and Drug Administration (FDA).
